Premium
Clinical manifestations of chronic inflammatory demyelinating polyneuropathy with anti‐cardiolipin antibodies
Author(s) -
Nakajima H.,
Shinoda K.,
Doi Y.,
Tagami M.,
Furutama D.,
Sugino M.,
Kimura F.,
Hanafusa T.
Publication year - 2005
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2005.00387.x
Subject(s) - medicine , chronic inflammatory demyelinating polyneuropathy , autoantibody , gastroenterology , polyneuropathy , anticardiolipin antibodies , antibody , weakness , immunology , surgery
Objective – Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune syndrome where certain autoantibodies define clinicopathologic subgroups. In the present study, serum anti‐cardiolipin antibodies (aCL) were evaluated. Materials and methods – We investigated aCL in sera from 21 patients diagnosed with CIDP in our hospital between 1991 and 2001. The four CIDP patients with aCL (aCL+) were compared with 17 patients without aCL (aCL−). Results – All aCL+ patients displayed sensory‐motor polyneuropathy, with severity and distribution of weakness resembling those in aCL− patients. Anti‐nuclear antibody titer of aCL+ patients were significantly higher than those in aCL− patients. None of aCL+ patients presented clinical manifestations of primary anti‐phospholipid syndrome (APS), such as thromboses or recurrent abortion. Although the aCL+ patients were older and had more complications and more severe pathologic features than aCL− patients, they responded well to steroid pulse or intravenous immunoglobulin. Conclusion – The aCL in CIDP apparently differ from ‘autoimmune’ aCL in APS, instead being among the autoantibodies pathologically involved in CIDP subgroups.